Skip to main content
TLSI logo

TLSI

TriSalus Life Sciences, Inc.

$2.31

6.39%

Trade Ideas Performance

Latest Closed Trade Idea

$2.31

6.39%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

3

Social

8

About

Events of TriSalus Life Sciences, Inc. (TLSI)

Over the past six months, TriSalus Life Sciences' stock declined by 15.85% from $4.67 to $3.93, with a 52-week range of $2.20 to $7.95. Year-to-date, the stock saw significant declines of 39.11% and 48.14%. In September 2026, FDA clearance for its TriNav Advance device led to a rise in shares. The Q2 2026 earnings report showed revenue beating estimates but a widened adjusted EBITDA loss, causing initial stock gains to slip. The company initiated the PREDICTT Clinical Trial for Liver Tumors in July and May 2026. An investigation was launched by Levi & Korsinsky in May 2026 regarding potential misleading statements. In August 2026, CMS expanded G-code reimbursement for TriNav into office-based labs. Analysts have given TLSI a consensus rating from "Hold" to "Strong Buy," with an average 12-month price target between $10.20 and $10.40.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)